|
|
 |
The majority of febrile neutropenia-related
events occur during the first
cycle of chemotherapy
Of those patients who developed febrile neutropenia, two thirds did
so in the first cycle of moderately myelosuppressive* chemotherapy
|
|
Incidence of febrile neutropenia events by cycle without
growth factor support6
|
 |
 |
Phase 3, multicenter, randomized, double-blind, placebo-controlled trial studied patients with breast cancer (N = 928)
randomly assigned to either placebo (n = 465) or Neulasta® (n = 463) on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel.
Patients who experienced febrile neutropenia in the double-blind phase of the study were converted to open-label
Neulasta® treatment for subsequent cycles of chemotherapy. |
|
|
|
| |
The incidence of Grade 3 and Grade 4 neutropenia was significantly reduced
across all cycles for patients receiving Neulasta® 7,8. |
|
|
|
Incidence of Grade 3 and Grade 4 neutropenia7,8
|
|
|
|
|
First- and subsequent-cycle Neulasta® virtually eliminated the risk of febrile neutropenia |
| |
Neulasta® significantly reduced the incidence of febrile neutropenia compared with placebo (P < .001) in breast cancer patients undergoing chemotherapy associated with ≥ 17% risk of developing febrile neutropenia (without growth factor support).6,9
Incidence of febrile neutropenia6,9
|
| |
|
|
First- and subsequent-cycle Neulasta® significantly reduced febrile neutropenia-related hospitalizations and IV anti-infective use for patients receiving moderate-risk* chemotherapy regimens |
| |
Neulasta® significantly reduced the incidence of hospitalizations (P < .001) and intravenous
(IV) anti-infective use associated with febrile neutropenia (P < .001) compared with placebo.6,9 |
|
Incidence of hospitalization and intravenous anti-infective use6,9
|
| |
|
|
*Regimens associated with ≥ 17% incidence of febrile neutropenia (temperature ≥ 38.2ºC and ANC < 0.5 x 109/L) in the absence of growth factor support. |
|
|
|
See Important Product Safety Information. |
|
|
